Real-world evidence and patient preference for subcutaneous intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis - initial results from the observational SISTER study.

Background: The consideration of patient preference for a certain drug route of administration (RoA) plays an important role in promoting patient adherence in chronic diseases. Natalizumab is an established treatment for relapsing-remitting multiple sclerosis (RRMS) and can be administered as intravenous (IV) infusion or subcutaneous (SC) injection developed to enable a shorter and easier administration IV RoA.

Study Objectives: Primary objective is to compare patients' preference for RoA and satisfaction with SC IV natalizumab at baseline and subsequent visits up to 12 months.